| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrew Hempel, Lilian Y Y Ma, Arthur Camerman, Donald Mastropaolo, Norman Camerma. 7,8-Dihydroxy-4-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolinium bromide monohydrate, a dopamine agonist. Acta crystallographica. Section C, Crystal structure communications. vol 61. issue Pt 12. 2006-12-05. PMID:16330847. |
structural comparison of the molecule with the ergoline dopamine agonist pergolide shows that it is the hydrogen-bond-forming hydroxy or imino group that is necessary for dopaminergic activity, rather than the presence of a phenyl or a pyrrole ring per se. |
2006-12-05 |
2023-08-12 |
Not clear |
| L M Epp, B Mrave. Chronic polysystemic candidiasis as a possible contributor to onset of idiopathic Parkinson's disease. Bratislavske lekarske listy. vol 107. issue 6-7. 2006-12-05. PMID:17051898. |
in the presence of acetaldehyde dopamine is converted into salsolinol, a neurotoxin involved in apoptosis of dopaminergic neurons. |
2006-12-05 |
2023-08-12 |
Not clear |
| D S Mathon, L J M J Vanderschuren, G M J Ramaker. Reduced psychostimulant effects on dopamine dynamics in the nucleus accumbens of mu-opioid receptor knockout mice. Neuroscience. vol 141. issue 4. 2006-12-04. PMID:16777349. |
in the present study we investigated whether these changes in dopaminergic cell bodies are accompanied by altered dopamine dynamics at the terminal level. |
2006-12-04 |
2023-08-12 |
mouse |
| M Aramideh, A W de Weer. [The restless legs syndrome can be treated with dopamine agonists]. Nederlands tijdschrift voor geneeskunde. vol 150. issue 40. 2006-11-30. PMID:17061425. |
rls can be treated successfully by dopaminergic agents, especially dopamine agonists. |
2006-11-30 |
2023-08-12 |
Not clear |
| Paola Sgadò, Lavinia Albéri, Daniel Gherbassi, Sherri L Galasso, Geert M J Ramakers, Kambiz N Alavian, Marten P Smidt, Richard H Dyck, Horst H Simo. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 41. 2006-11-28. PMID:17015829. |
specifically, postnatal mutant mice exhibit a progressive degeneration of dopaminergic neurons in the substantia nigra during the first 3 mo of their lives, leading to diminished storage and release of dopamine in the caudate putamen, motor deficits similar to akinesia and bradykinesia, and a lower body weight. |
2006-11-28 |
2023-08-12 |
mouse |
| Sanjay Jain, Judith P Golden, David Wozniak, Elizabeth Pehek, Eugene M Johnson, Jeffrey Milbrand. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 43. 2006-11-24. PMID:17065462. |
to delete ret specifically in dopaminergic neurons and determine the physiologic requirement of ret in the maintenance of substantia nigra compacta (snc) and ventral tegmental area (vta), we bred the ret conditional mice with mice that specifically express cre from the dopamine transporter (dat) locus. |
2006-11-24 |
2023-08-12 |
mouse |
| Sanjay Jain, Judith P Golden, David Wozniak, Elizabeth Pehek, Eugene M Johnson, Jeffrey Milbrand. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 43. 2006-11-24. PMID:17065462. |
a detailed morphometric and biochemical analysis including dopaminergic neuron number and size in snc and vta, and fiber density in the striatum and nucleus accumbens, and dopamine levels indicate that ret is not required for providing global trophic support to midbrain dopaminergic neurons in adult mice. |
2006-11-24 |
2023-08-12 |
mouse |
| Zhiming Zhang, Anders H Andersen, Yi Ai, Aaron Loveland, Peter A Hardy, Greg A Gerhardt, Don M Gas. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. NeuroImage. vol 33. issue 2. 2006-11-21. PMID:16949305. |
the primary findings were (1) the putamen and substantia nigra (sn) but not the caudate nucleus displayed significant bold responses to these dopaminergic drugs; (2) a significant relationship was found between amphetamine-evoked activation and the number of surviving dopamine neurons in the sn, which was also correlated with bradykinesia; and (3) inverse relationships were seen in response to apomorphine and amphetamine stimulation between the mptp-lesioned and unlesioned putamen and sn. |
2006-11-21 |
2023-08-12 |
monkey |
| Anthony H V Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A Obeso, Michael A Schwarzschild, Umberto Spampinato, Giora Davida. Novel pharmacological targets for the treatment of Parkinson's disease. Nature reviews. Drug discovery. vol 5. issue 10. 2006-11-20. PMID:17016425. |
dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of parkinson's disease. |
2006-11-20 |
2023-08-12 |
Not clear |
| Christoph Scherfler, Naheed L Khan, Nicola Pavese, Andrew J Lees, Niall P Quinn, David J Brooks, Paola P Piccin. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Movement disorders : official journal of the Movement Disorder Society. vol 21. issue 6. 2006-11-14. PMID:16511856. |
upregulation of dopamine d2 receptors in dopaminergic drug-naive patients with parkin gene mutations. |
2006-11-14 |
2023-08-12 |
Not clear |
| Brad J Kolls, Mark Stac. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clinical neuropharmacology. vol 29. issue 5. 2006-11-14. PMID:16960475. |
in advance-stage disease, fluctuations in motor function, variability in response to dopaminergic therapy, and dyskinesias related to increasing doses of dopamine agonists and levodopa, present a variety of challenges to a managing physician. |
2006-11-14 |
2023-08-12 |
Not clear |
| Yan Xiang Yang, Miratul M K Muqit, David S Latchma. Induction of parkin expression in the presence of oxidative stress. The European journal of neuroscience. vol 24. issue 5. 2006-11-14. PMID:16987221. |
we demonstrated here that parkin is up-regulated when sh-sy5y dopaminergic neuroblastoma cells are exposed to the oxidant dopamine. |
2006-11-14 |
2023-08-12 |
Not clear |
| Geeta Ravindran, Harinarayana S Ra. Enriched NCAM-positive cells form functional dopaminergic neurons in the rat model of Parkinson's disease. Stem cells and development. vol 15. issue 4. 2006-11-13. PMID:16978060. |
the predifferentiated cells when analyzed by rt-pcr showed expression of dopaminergic markers such as nurr1, engrailed-1, aromatic amino decarboxylase (aadc), vmat2, tyrosine hydroxylase (th), and dopamine transporter (dat). |
2006-11-13 |
2023-08-12 |
human |
| Ramón Soto-Otero, Carolina Sanmartín-Suárez, Sofía Sánchez-Iglesias, Alvaro Hermida-Ameijeiras, Inés Sánchez-Sellero, Estefanía Méndez-Alvare. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease. Journal of biochemical and molecular toxicology. vol 20. issue 5. 2006-11-13. PMID:17009235. |
tetrahydropapaveroline (thp) is a compound derived from dopamine monoamine oxidase-mediated metabolism, particularly present in the brain of parkinsonian patients receiving l-dopa therapy, and is capable of causing dopaminergic neurodegeneration. |
2006-11-13 |
2023-08-12 |
Not clear |
| Janusz K Rybakowski, Alina Borkowska, Piotr M Czerski, Monika Dmitrzak-Weglarz, Maria Skibinska, Pawel Kapelski, Joanna Hause. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry research. vol 143. issue 1. 2006-11-09. PMID:16712949. |
the aim of the study was to test an association between polymorphisms of genes connected with dopaminergic inactivation in prefrontal cortex [catechol-o-methyltransferase (comt), dopamine transporter (dat), norepinephrine transporter (net)], and performance on the wisconsin card sorting test (wcst), in schizophrenic patients. |
2006-11-09 |
2023-08-12 |
cat |
| A Bender, W Koch, M Elstner, Y Schombacher, J Bender, M Moeschl, F Gekeler, B Müller-Myhsok, T Gasser, K Tatsch, T Klopstoc. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. vol 67. issue 7. 2006-11-08. PMID:17030762. |
cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall unified parkinson's disease rating scale scores or dopamine transporter spect. |
2006-11-08 |
2023-08-12 |
Not clear |
| Ella H Sklan, Amit Berson, Klara R Birikh, Amos Gutnick, Or Shahar, Shai Shoham, Hermona Sore. Acetylcholinesterase modulates stress-induced motor responses through catalytic and noncatalytic properties. Biological psychiatry. vol 60. issue 7. 2006-11-07. PMID:16904653. |
more specifically, we induced stress-associated hypofunction of dopaminergic, mainly d2 dopamine receptor-mediated neurotransmission by haloperidol and explored stress induced hyperlocomotion and catalepsy, an extreme form of immobility, induced in mice with ache deficiencies. |
2006-11-07 |
2023-08-12 |
mouse |
| Faneng Sun, Vellareddy Anantharam, Danhui Zhang, Calivarathan Latchoumycandane, Arthi Kanthasamy, Anumantha G Kanthasam. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology. vol 27. issue 5. 2006-10-31. PMID:16870259. |
collectively, these results demonstrate that the proteasomal inhibitor mg-132 induces dopamine depletion and nigral dopaminergic degeneration in both cell culture and animal models, and suggest that proteasomal dysfunction may promote nigral dopaminergic degeneration in parkinson's disease. |
2006-10-31 |
2023-08-12 |
mouse |
| Ubaldo Bonuccelli, Paolo Del Dott. New pharmacologic horizons in the treatment of Parkinson disease. Neurology. vol 67. issue 7 Suppl 2. 2006-10-30. PMID:17030738. |
the nonphysiologic pulsatile stimulation of striatal dopamine receptors, produced by the currently available dopaminergic drugs, may trigger a dysregulation of many neurotransmitter systems within the basal ganglia, mainly localized on medium spiny striatal neurons. |
2006-10-30 |
2023-08-12 |
Not clear |
| Ji-Kyung Choi, Y Iris Chen, Edith Hamel, Bruce G Jenkin. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. NeuroImage. vol 30. issue 3. 2006-10-26. PMID:16459104. |
together, these experiments show that direct effects of dopamine upon the vasculature cannot be ignored in measuring the hemodynamic coupling associated with dopaminergic drugs. |
2006-10-26 |
2023-08-12 |
Not clear |